September 23, 2019 | Vensana in the News

New Minnesota-based fund has $225 million to invest in young med-tech companies

20

Novel FDA PMA & de novo 510k approvals

55

U.S. Commercial Product Launches

39

Level I Clinical Trials

29

Strategic Financings

31

Exits by IPO or M&A